These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 35414106)
21. Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis. Labenz C; Kostev K; Galle PR; Wörns MA; Labenz J; Tanislav C; Adarkwah CC Medicine (Baltimore); 2020 Dec; 99(50):e23436. PubMed ID: 33327272 [TBL] [Abstract][Full Text] [Related]
22. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. Terg R; Casciato P; Garbe C; Cartier M; Stieben T; Mendizabal M; Niveyro C; Benavides J; Marino M; Colombato L; Berbara D; Silva M; Salgado P; Barreyro F; Fassio E; Gadano A; J Hepatol; 2015 May; 62(5):1056-60. PubMed ID: 25481567 [TBL] [Abstract][Full Text] [Related]
23. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark. Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115 [TBL] [Abstract][Full Text] [Related]
24. Infection risk and management strategies for patients with cirrhosis taking proton pump inhibitors. Zerr B; Vazquez A; Erstad BL Am J Health Syst Pharm; 2023 Jul; 80(15):967-973. PubMed ID: 37105716 [TBL] [Abstract][Full Text] [Related]
26. The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial. Casper M; Mengel M; Fuhrmann C; Herrmann E; Appenrodt B; Schiedermaier P; Reichert M; Bruns T; Engelmann C; Grünhage F; Lammert F; Trials; 2015 Mar; 16():83. PubMed ID: 25887140 [TBL] [Abstract][Full Text] [Related]
27. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. Bajaj JS; Acharya C; Fagan A; White MB; Gavis E; Heuman DM; Hylemon PB; Fuchs M; Puri P; Schubert ML; Sanyal AJ; Sterling RK; Stravitz TR; Siddiqui MS; Luketic V; Lee H; Sikaroodi M; Gillevet PM Am J Gastroenterol; 2018 Aug; 113(8):1177-1186. PubMed ID: 29872220 [TBL] [Abstract][Full Text] [Related]
28. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Chan FK; Wong VW; Suen BY; Wu JC; Ching JY; Hung LC; Hui AJ; Leung VK; Lee VW; Lai LH; Wong GL; Chow DK; To KF; Leung WK; Chiu PW; Lee YT; Lau JY; Chan HL; Ng EK; Sung JJ Lancet; 2007 May; 369(9573):1621-6. PubMed ID: 17499604 [TBL] [Abstract][Full Text] [Related]
29. Safe use of proton pump inhibitors in patients with cirrhosis. Weersink RA; Bouma M; Burger DM; Drenth JPH; Harkes-Idzinga SF; Hunfeld NGM; Metselaar HJ; Monster-Simons MH; van Putten SAW; Taxis K; Borgsteede SD Br J Clin Pharmacol; 2018 Aug; 84(8):1806-1820. PubMed ID: 29688583 [TBL] [Abstract][Full Text] [Related]
30. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494 [TBL] [Abstract][Full Text] [Related]
31. Proton Pump Inhibitor Therapy Is Associated With Reduction of Early Bleeding Risk After Prophylactic Endoscopic Variceal Band Ligation: A Retrospective Cohort Study. Kang SH; Yim HJ; Kim SY; Suh SJ; Hyun JJ; Jung SW; Jung YK; Koo JS; Lee SW Medicine (Baltimore); 2016 Feb; 95(8):e2903. PubMed ID: 26937932 [TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies. Wu X; Zhang D; Yu Y; Lou L; Li X Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32406491 [TBL] [Abstract][Full Text] [Related]
33. Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis. Wong ZY; Koh JH; Muthiah M; Koh B; Ong EYH; Ong CEY; Ou KQ; Lim WH; Tan DJH; Chee D; Siah KTH; Wong Y; Kaewdech A; Wijarnpreecha K; Kulkarni AV; Nah B; Huang DQ; Noureddin M; Ng CH; Teng M Dig Dis Sci; 2024 Jan; 69(1):289-297. PubMed ID: 37968557 [TBL] [Abstract][Full Text] [Related]
34. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452 [TBL] [Abstract][Full Text] [Related]
35. Proton pump inhibitors in critically ill mechanically ventilated patients with COVID-19: protocol for a substudy of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial. Dennis BB; Thabane L; Heels-Ansdell D; Dionne JC; Binnie A; Tsang J; Guyatt G; Ahmed A; Lauzier F; Deane A; Arabi Y; Marshall J; Zytaruk N; Saunders L; Finfer S; Myburgh J; Muscedere J; English S; Ostermann M; Hardie M; Knowles S; Cook D; Trials; 2023 Aug; 24(1):561. PubMed ID: 37644556 [TBL] [Abstract][Full Text] [Related]
36. High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study. Yoon JS; Hong JH; Park SY; Kim SU; Kim HY; Kim JY; Hur MH; Park MK; Lee YB; Lee HA; Kim GA; Sinn DH; Park SJ; Lee YJ; Kim YJ; Yoon JH; Lee JH Aliment Pharmacol Ther; 2024 Apr; 59(8):973-983. PubMed ID: 38389319 [TBL] [Abstract][Full Text] [Related]
37. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial. Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441 [TBL] [Abstract][Full Text] [Related]
38. Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy. Sung JJ; Suen BY; Wu JC; Lau JY; Ching JY; Lee VW; Chiu PW; Tsoi KK; Chan FK Am J Gastroenterol; 2014 Jul; 109(7):1005-10. PubMed ID: 24777150 [TBL] [Abstract][Full Text] [Related]
39. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Mahmud N; Serper M; Taddei TH; Kaplan DE Gastroenterology; 2022 Jul; 163(1):257-269.e6. PubMed ID: 35398042 [TBL] [Abstract][Full Text] [Related]
40. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial. Nickols NG; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Might M; Goldstein DB; Wang X; Ramoni R; Myrie K; Tran S; Ghayouri L; Tsai S; Geelhoed M; Makarov D; Becker DJ; Tsay JC; Diamond M; George A; Al-Ajam M; Belligund P; Montgomery RB; Mostaghel EA; Sulpizio C; Mi Z; Dematt E; Tadalan J; Norman LE; Briones D; Clise CE; Taylor ZW; Huminik JR; Biswas K; Rettig MB Trials; 2021 Jul; 22(1):431. PubMed ID: 34225789 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]